Myc proto-oncogene protein, Estrogen receptor alpha, and Hypoxia-inducible factor 1-alpha Network (MYC/ESR1/HIF1A)

The MYC, ESR1, and HIF1A network represents a critical regulatory axis in oncology, integrating signals for cell proliferation, hormonal response, and adaptation to hypoxia. MYC is a master transcription factor that regulates thousands of genes involved in cell cycle progression and metabolism, often overexpressed in a wide range of human cancers (UniProt P01106). ESR1, or Estrogen Receptor Alpha, is a ligand-activated transcription factor essential for mammary gland development and a primary driver in ER-positive breast cancers (UniProt P03372). HIF1A serves as the master transcriptional regulator of the adaptive response to low oxygen, promoting angiogenesis and glycolytic metabolism to support tumor survival in poorly vascularized environments (UniProt Q16665). These three factors are deeply interconnected; for instance, MYC and HIF1A cooperatively regulate metabolic reprogramming, while ESR1 can modulate MYC expression in breast cancer cells (PubMed: 21623347). Targeting this network is a major focus of drug development, ranging from established endocrine therapies for ESR1 to emerging direct and indirect inhibitors for the historically difficult-to-drug MYC and HIF1A proteins (PubMed: 30215594). Clinical challenges include the development of resistance mutations in ESR1 and the high potential for systemic toxicity when inhibiting the broadly essential MYC protein.

Other names

c-MycER-alphaHIF-1-alphaESR1MYCHIF1ATranscription factor 1NR3A1

Competitive antagonism of ligand binding (ESR1), selective estrogen receptor degradation (SERDs), inhibition of protein-protein dimerization (MYC/MAX or HIF1A/ARNT), and transcriptional repression via epigenetic modulation (BET inhibitors).